Beam Therapeutics
Logotype for Beam Therapeutics Inc

Beam Therapeutics (BEAM) investor relations material

Beam Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Beam Therapeutics Inc
3rd Annual Guggenheim Healthcare Innovation Conference summary10 Nov, 2026

Editing platform

  • Base editing uses RNA-guided Cas9 targeting without double-stranded DNA breaks; attached deaminase enzymes enable A-to-G or C-to-T changes.

  • Four programs are in clinical development, spanning ex vivo sickle cell treatment and in vivo LNP-based editing for liver diseases.

Risto-cel for sickle cell disease

  • BEACON met all primary and secondary efficacy and safety endpoints; a BLA filing is targeted as early as year-end 2026.

  • Risto-cel showed the highest reported hemoglobin F, reduced hemoglobin S below 40%, normalized hemoglobin, and reduced blood viscosity.

  • Automated manufacturing supports reliable dosing; median mobilization was one, with the vast majority of trial participants requiring two or fewer mobilizations.

  • Dose is 3.5 million cells/kg; base editing requires fewer starting cells, while faster neutrophil engraftment may reduce infection risk and hospital stays.

In vivo programs

  • BEAM-302 for alpha-1 antitrypsin deficiency is in pivotal phase; FDA agreement supports accelerated approval, with pivotal completion expected in H1 2027.

  • At 60 mg, all patients reached the 11-micromolar total AAT threshold or higher; the FDA viewed the biomarker dataset as approvable for accelerated approval.

  • BEAM-301 for G6PC R83C showed two patients at 40 mg fasting for 15 hours versus a prior maximum of two hours; dose escalation is proceeding to 60 mg.

  • One BEAM-301 participant responded less, with compound heterozygosity and BMI 53 cited as possible factors; lower-dose participants are expected eventually to receive the optimal biological dose, without a timeline.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Beam Therapeutics earnings date

Logotype for Beam Therapeutics Inc
UBS Global Biopharma Conference 202617 Nov, 2026
Beam Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Beam Therapeutics earnings date

Logotype for Beam Therapeutics Inc
UBS Global Biopharma Conference 202617 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Beam Therapeutics Inc is a biotechnology company focused on the development of precision genetic medicines using base editing technology. The company’s approach aims to correct genetic mutations at the single-base level to treat various diseases, including genetic disorders and cancers. It conducts research and development in-house and through collaborations. Beam Therapeutics Inc is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.